Vanda Reports Third-Quarter 2026 Results

Third-quarter results

Vanda Pharmaceuticals reported financial and operational results for the third quarter ended September 30, 2026, according to TradingView’s coverage of a PRNewswire announcement published October 28, 2026.

Vanda said revenue increased 24% year over year in the third quarter. In the announcement summary carried by TradingView, the company described the revenue growth as strong.

The available summary states that the growth was driven by factors referenced in Vanda’s announcement. It does not identify individual products, commercial programs, financial line items, or operational measures behind that result.

Company-level commercial update

The quarterly update covers both financial and operational results for Vanda. TradingView identified the company as Vanda Pharmaceuticals Inc. and listed its Nasdaq ticker as VNDA.

For pharmaceutical and biotech sales professionals, the reported revenue figure provides a company-level view of Vanda’s third-quarter performance. The supplied evidence does not break out results by product, customer segment, geography, territory, or sales channel.

It also does not provide information on sales-force changes, commercial priorities, pipeline activity, guidance, or future performance. Those subjects are not addressed in the supplied release summary and are therefore outside the scope of this update.

Source and timing

TradingView published the report under the headline Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results. The item cites a PRNewswire announcement dated October 28, 2026.

The results cover the quarter ended September 30, 2026. Vanda’s reported 24% year-over-year revenue increase is the specific performance measure included in the supplied evidence.

Additional detail on the company’s financial and operational results is not included in the available summary.